Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsZyduslifesciences

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Adani Enterprises, Dena Bank, Cadila Health: Prabhakar

      AK Prabhakar, Independent Advisor recommends buying Adani Enterprises with a target of Rs 273 and Dena Bank with a target of Rs 63.

    • Bull's Eye: Buy Arvind, Dena Bank, Tech Mahindra, YES Bank

      Shahina Mukadam of Varun Capital recommends buying Tata Motors (DVR) with a target of Rs 196 and Allahabad Bank with a target of Rs 86.

    • 6 trading stocks for short term gain

      Vikrant Jadeja of Vibrant Trades suggests buying Gail India with a target of Rs 345 and Cadila Healthcare with a target of Rs 780.

    • Sell Wockhardt on rally: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking advises selling Wockhardt on rallies.

    • Hold Sun Pharma, book profits on Lupin now: AnandRathi

      Rathi recommends booking profit in Lupin at current valuations. He has a neutral rating and a ‘hold‘ on the Sun Pharma stock because there are several triggers which can drive the earning surprise positively

    • Check out Dipan Mehta's top bets in IT & pharma space

      Dipan Mehta is overweight on IT sector with rupee depreciating. Among the pharma stocks, he likes Sun Pharma, Dr Reddy's, Wockhardt and Cadila.

    • Avoid Cadila Healthcare, says Sukhani

      Sudarshan Sukhani of s2analytics.com advises traders to avoid Cadila Healthcare.

    • Year 2013: 11 stocks that can give you handsome returns

      Moneycontrol.com got AK Prabhakar, senior VP-equity research, Anand Rathi to answer the stock queries you sent us on our Facebook page as part of KYI (Know Your Investment). Check out his comments.

    • New drug pricing policy: Which cos will be impacted most?

      Chirag Talati, Espirito Santo Securities says the policy had been anticipated for long. According to him, Cipla, Cadila and Ranbaxy will be impacted negatively.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • Buy Cadila Healthcare, says PN Vijay

      Buy Cadila Healthcare with a target price of about Rs 975, says PN Vijay, Portfolio Manager.

    • Top 10 intraday and long-term bets to beat volatility

      The Indian market has swung like a pendulum over the last many sessions. Stock picking is very important during the volatile times. There are many opportunities for the investors.

    • Super Six short term picks for Sept 12

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Sanjeev Agarwal of Dynamix Research & Capital Management and Manav Chopra of Nirmal Bang, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Two pharma stocks that can improve health of your portfolio

      Ranbaxy and Cipla were at 52 week highs on Monday. Kour expects Cipla to perform well going ahead. She is bullish on this stock; however, she is cautious on Ranbaxy.

    • Super Six stocks you can bet on August 31

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Rajesh Jain of Religare Securities and Shardul Kulkarni of Angel Broking, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Drug makers in India to sustain 'premium' valuations: HSBC

      HSBC raises target prices for some Indian drug makers saying "robust" earnings will help sustain the "premium" valuations in the sector.

    • Bull's Eye: Buy IGL, Jubilant Food; short BGR, Educomp

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Bull's Eye: Buy Alstom Projects, Apollo Tyre, Godrej Ind

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Houseviews: Brokerages call on four stocks!

      Merrill Lycnh retains its underperform call on M&M with a target of Rs 645. Despite an 8% beat in realizations on sales mix, profit, adjusting for the reversal of forex charges, grew just 1%, which was well below street estimates.

    • Zydus Wellness can move above Rs 600: SP Tulsian

      Zydus Wellness can move above Rs 600, says SP Tulsian, sptulsian.com.

    • Hold Cadila Healthcare: Salil Sharma

      Salil Sharma of Kapoor Sharma and Company feels that one should hold Cadila Healthcare.

    • Buy Cadila Healthcare on dips: Angel Broking

      Buy Cadila Healthcare on dips, says Sarabjit Kour Nangra, VP - Research, Angel Broking.

    • Lupin, Cadila may give excellent returns: PN Vijay

      Lupin and Cadila may give excellent returns, says PN Vijay, Portfolio Manager.

    • PN Vijay view on Cadila Healthcare

      Cadila Healthcare has a great appeal to people and has got a strong domestic formulation business about 31-32%, says PN Vijay, Portfolio Manager.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347